PUK12 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND 10 MGVERSUS FESOTERODINE 4 MG AND 8 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK NHS
Nov 1, 2008, 00:00
10.1016/S1098-3015(10)67126-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)67126-4/fulltext
Title :
PUK12 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND 10 MGVERSUS FESOTERODINE 4 MG AND 8 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK NHS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67126-4&doi=10.1016/S1098-3015(10)67126-4
First page :
Section Title :
Open access? :
No
Section Order :
961